10/26/2009 | CV | Medarex tender offer for 2.25% convertibles expires; no notes tendered
|
9/24/2009 | CV | Medarex holders may put 2.25% convertibles following change of control
|
9/1/2009 | SS | Bristol-Myers Squibb completes $16-per-share purchase of Medarex
|
8/27/2009 | SS | Bristol-Myers Squibb begins offer for remaining Medarex shares
|
8/20/2009 | SS | Bristol-Myers Squibb extends tender offer for Medarex by two days
|
8/19/2009 | SS | Medarex investor Gamco buys shares ahead of Bristol-Myers merger
|
7/28/2009 | SS | Bristol-Myers Squibb's tender offer for Medarex shares ends Aug. 24
|
7/24/2009 | CV | Market Commentary: Intel eyed as volume name; Ingersoll-Rand, Actuant strong; Human Genome gains more; Medarex over par
|
7/24/2009 | SS | Market Commentary: Bristol-Meyers predicted to continue deal pace; proxy firm sides with Foundation Coal buyout
|
7/23/2009 | SS | Market Commentary: Bristol-Myers' buy narrows drug field; Noven tender opens; TransAlta offer considered risky
|
7/23/2009 | SS | Bristol-Myers Squibb, Medarex to combine in deal worth $2.4 billion
|
6/27/2008 | SP | New Issue: RBC prices $0.13 million 20% reverse convertibles linked to Medarex
|
6/27/2008 | SP | New Issue: RBC prices $0.309 million 18.25% reverse convertibles linked to Medarex
|
6/11/2008 | SP | RBC plans 18.25% reverse convertibles linked to Medarex
|
6/11/2008 | SP | RBC plans 20% reverse convertibles linked to Medarex
|
12/11/2007 | CV | Market Commentary: WaMu resets price talk on preferreds; Countrywide, Fannie Mae, homebuilders hammered after rate cut
|
10/30/2007 | SP | New Issue: RBC prices $317,000 25.75% reverse convertibles linked to Medarex
|
10/9/2007 | SP | RBC to price 25.75% reverse convertibles linked to Medarex
|
8/23/2007 | SP | New Issue: HSBC sells $1.75 million 18.25% reverse convertibles linked to stock basket
|
5/8/2007 | SP | New Issue: HSBC sells $2.701 million 15% reverse convertibles linked to four stocks
|
11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
10/4/2006 | BTCVDD | Medarex receives consents to amend 2.25% convertibles
|
10/2/2006 | BTCVDD | Medarex amends solicitation for 2.25% convertibles, eliminates fee, adds call protection
|
9/22/2006 | BTCVDD | Medarex seeks consents to amend 2.25% convertibles after default notice
|
9/11/2006 | BT | Medarex sets goal of filing INDs for three new products each year going forward
|
9/6/2006 | BT | Medarex, Massachusetts Biologic Labs begin phase 2 trial in diarrhea
|
8/31/2006 | BTCVDD | Medarex receives default notice on 2.25% convertibles for failure to file 10-Q
|
8/22/2006 | BT | Medarex to collaborate with GenPat77 on human antibody therapeutics
|
8/18/2006 | BT | Medarex to restate financials, faces possible Nasdaq delisting
|
6/26/2006 | BT | Euroscreen, Medarex sign licensing deal to develop antibody products against two targets
|
6/22/2006 | BT | Celera Genomics, Medarex to develop therapeutic antibodies for treatment of cancer
|
6/19/2006 | BT | Medarex to start ipilimumab trial
|
6/15/2006 | BT | Medarex subpoenaed over stock option grant practices
|
6/5/2006 | BT | Medarex: ipilimumab decreases prostate specific antigen levels by 50%
|
5/24/2006 | BT | Medarex says SEC investigating stock option grants
|
5/12/2006 | BT | Medarex subsidiary Celldex appoints new chief executive officer
|
5/10/2006 | BT | Oxford Genome Sciences, Medarex to collaborate on cancer treatments
|
5/8/2006 | BT | Medarex greenshoe exercised, raising public stock offering to 11.5 million shares
|
5/5/2006 | BT | Medarex reports 1Q net loss shrinks to $36 million, revenues increase
|
4/7/2006 | BT | New Issue: Medarex raises $117.5 million in follow-on of 10 million shares at $11.75 each vs. $12.28 close
|
4/7/2006 | BT | Market Commentary: Medarex slides; Biomet gains on anticipated sale; Cell Therapeutics higher; Acusphere dives on PIPE
|
4/6/2006 | BT | Medarex reports MDX-010 trial results following stock offering
|
4/6/2006 | BT | Market Commentary: Amgen a drag on biotech sector; Medarex follow-on seen on deck; Oscient up on PIPE after-hours
|
4/3/2006 | BT | Market Commentary: Epix up 21% on Predix buy; Incyte falls 41%; Medarex off; Inhibitex plunges 66%; StemCells dives
|
4/3/2006 | BT | Medarex launches follow-on of 10 million shares via Goldman, J.P. Morgan
|
3/31/2006 | BT | Medarex begins registrational trial of ipilimumab for metastatic melanoma
|
3/28/2006 | BT | Medarex grants Diatos full European rights to cancer drug DTS-201
|
3/28/2006 | BT | Ono, Medarex enter second collaboration to develop fully human antibody therapeutic
|
3/6/2006 | BT | Medarex loss tightens to $146 million, revenue quadruples to $51.5 million in 2005
|
3/6/2006 | BT | FDA grants orphan drug status to Medarex's Valortim to treat anthrax infection
|
2/1/2006 | BT | Medarex, Organon sign deal to develop therapeutic antibodies
|
1/30/2006 | BT | Medarex gets milestone from ImClone for IgG1's accepted Investigational New Drug Application
|
1/19/2006 | BT | Medarex says licensing partner files IND, triggers milestone payment
|
1/19/2006 | BT | Medarex at peer perform by Thomas Weisel
|
1/9/2006 | BT | PharmAthene, Medarex receive FDA fast track designation for anthrax antibody
|
12/16/2005 | BT | Market Commentary: Amgen, Abgenix easier; takeover talk fuels rise in Imclone, several other biotechs; Kos slide continues
|
11/15/2005 | BT | Medarex to receive milestone payment from Bristol-Myers Squibb for anti-cancer antibody
|
8/31/2005 | BT | Market Commentary: MedImmune shoots up over 10%; Chiron little changed; Glaxo gains on U.S. flu shot OK; Oscient flat
|
8/12/2005 | BT | Market Commentary: Electro-Optical seen pricing Tuesday; Coley, China Medical mixed; Alexion slips; Isis convertible bid up
|
1/14/2005 | CV | Medarex says all $147 million 4.25% notes converted ahead of redemption
|
12/15/2004 | CV | Medarex calls all $147 million 4.25% convertibles
|
12/7/2004 | CV | Market Commentary: CMS new deal bid at issue; Dress Barn bid up 3.5 points; Seacor launches overnighter
|
11/8/2004 | PP | Market Commentary: Private placement action moderate in mixed market; Medarex gets $50 million in licensing deal
|
11/8/2004 | PP | New Issue: Medarex receives $50 million up front, part of up to $205 million licensing agreement
|
5/27/2004 | CV | Medarex to call 4.5% convertible subordinated notes
|
4/30/2004 | CV | Market Commentary: Conseco deal seen May 3 week after delay due to warning; price talk emerges on Genworth deal
|
4/28/2004 | CV | New Issue: Medarex upsized $150 million convertible yields 2.25%, up 30%
|
4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
4/26/2004 | CV | Medarex $125 million convertible talked at 2.25-2.75%, up 25-30%
|
4/26/2004 | CV | Market Commentary: OSI Pharma skyrockets amid buying frenzy as stock shoots up 139%; 4 new deals emerge
|
4/26/2004 | CV | Medarex to repurchase, redeem 4.5% convertibles
|
7/22/2003 | CV | Medarex greenshoe exercised, raising convertibles to $125 million
|
7/18/2003 | CV | New Issue: Medarex sells $100 million convertible at 4.25%, up 27.5%
|
7/17/2003 | CV | Medarex $100 million convertible talked to yield 3.75-4.25%, up 27.5-32.5%
|
7/17/2003 | CV | Market Commentary: Market slides sharply, thanks to Nasdaq, but uptick in volatility gives some encouragement
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
2/4/2002 | CV | Market Commentary: Convertibles plunge as stocks dive, Solutia nixes new deal
|